Biotech News
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
FORTIFY, a Phase 1b indication expansion trial of PLN-101095, continues strong enrollment Pliant’s proprietary selective, targeted, integrin-mediated delivery platform demonstrates encouraging initial preclinical results Strengthened leadership team with appointments of David Raben, M.D., as Chief
